Prof. Dr. Claus R. Bartram
Director Institute of Human Genetics, Heidelberg
Dean, Medical Faculty Heidelberg

2.8.1952

Institute of Human Genetics
Im Neuenheimer Feld 366
69120 Heidelberg

06221-565151 (phone)
06221-565155 (fax)
cr_bartram@med.uni-heidelberg.de

SCIENTIFIC VITA

1978	Graduation (Medicine) and M.D. degree (summa cum laude), University of Hamburg
1979 - 1982	Specialization in Pediatrics at the University Childrens' Hospital in Düsseldorf
1982 - 1983	DFG Scholarship at the Erasmus University Rotterdam, Department of Cell Biology and Genetics
1984 - 1985	Specialization in Pediatrics at the University Childrens' Hospital in Ulm Board Certification in Pediatrics (1988)
1985	Habilitation (Pediatrics) at the University of Ulm
1987	Associate Professor and Head of the Section Molecular Biology, Department of Pediatrics II, University of Ulm
1993	Appointed to the Chair of Clinical Molecular Biology at the University of Ulm Board Certification in Human Genetics (1995).
1995	Appointed to the Chair of Human Genetics at the University of Heidelberg Director of the Institute of Human Genetics, University of Heidelberg (01.10.1995)
1999	Appointmented to the Chair of Clinical Genetics at the Erasmus University in Rotterdam (declined)

AWARDS

Science Award from the Kind-Philipp-Foundation for Leukemia Research (1984); Science Award from the City of Ulm (1987); The Artur Pappenheim Award from the German Society for Hematology and Oncology (1989); Science Award from the Johann Georg Zimmermann Foundation for Cancer Research (1990); Mildred Scheel Memorial Lecture from the German Cancer Aid (1992); Robert Pfleger Award from the Dr. Robert Pfleger Foundation (1992); The Wilhelm Warner Foundation Science Award (1993); Merckle Award for Research from the University of Ulm (1994); Redlich Memorial Lectureship in Hematology, Visiting Professor at the Cedars-Sinai Medical Center, UCLA (1995); Lingen Foundation Science Award (1996); German Cancer Aid Award (2000)

FIELDS OF INTEREST

Cancer genetics, molecular characterization of hematopoietic neoplasias, minimal residual disease, hereditary cancer disposition.

SELECTED PUBLICATIONS

Wirtenberger M, Frank B, Hemminki K, Klaes R, Schmutzler RK, Wappenschmidt B, Meindl A, Kiechle M, Arnold N, Weber BH, Niederacher D, Bartram CR, Burwinkel B (2006). Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. **Carcinogenesis** 27, 1655-1660

Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Welte K, Ludwig WD, Bartram CR, Zanger UM, Eichelbaum M, Schrappe M, Schwab M (2005). Thiopurine methyltransferase (TPMT) genotype is an independent modulator of early treatment response to 6-mercaptopurine in childhood acute lymphoblastic leukaemia. **JAMA** 293, 1485-1489

Cario G, Stanulla M, Fine BM, Teuffel O, v Neuhoff N, Schrauder A, Flohr T, Schafer BW, Bartram CR, Welte K, Schlegelberger B, Schrappe M (2005). Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. **Blood** 105, 821-826

Willemse MJ, Seriu T, d'Aniello E, Hop WCJ, Panzer-Grumayer ER, Biondi A, Schrappe M, Kamps WA, Masera G, Gadner H, Riehm H, Bartram CR, van Dongen JJM (2002). Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor-B-ALL. **Blood** 99, 4386-4393

Gleißner B, Gokbuget N, Bartram CR, Janssen LAJ, Rieder H, Janssen JWG, Fonatsch C, Heyll A, Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E (2002). Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. **Blood** 99, 1536-1543

Tsukasaki K, Krebs J, Nagai K, Tomonaga M, Koeffler HP, Bartram CR, Jauch A (2001). Comparative genomic hybridization (CGH) analysis of adult T-cell leukemia/lymphoma (ATL): correlation with clinical course. **Blood** 97, 3875-3881

Janssen JWG, Vaandrager JW, Heuser T, Jauch A, Kluin PM, Geelen E, Bergsagel PL, Kuehl WM, Drexler HG, Otsuki T, Bartram CR, Schuuring E (2000). Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). **Blood** 95, 2691-2698, 2000.

Kamatsu N, Takeuchi S, Ikezoe T, Tasaka T, Hatta Y, Machida H, Williamson IK, Bartram CR, Koeffler HP, Taguchi H (2000). Mutations of the E2F4 gene in hematological malignancies having microsatellite instability. **Blood** 95, 1509-1510

Nakao M, Janssen JW, Flohr T, Bartram CR (2000). Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. **Cancer Res** 60, 3281-3289

Van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MAC, Cazzaniga G, Hettinger K, van der Does-van der Berg A, Hop WCJ, Riehm H, Bartram CR (1998). Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. **Lancet** 352, 1731-1738